Correction: Triglyceride-glucose index and subclinical left ventricular dysfunction across cardiovascular-kidney-metabolic syndrome stages: a 7-year retrospective cohort study - Report - MDSpire

Correction: Triglyceride-glucose index and subclinical left ventricular dysfunction across cardiovascular-kidney-metabolic syndrome stages: a 7-year retrospective cohort study

  • By

  • Kun-Zhe Tsai

  • Gen-Min Lin

  • Chunho Yun

  • Kuotzu Sung

  • Charles Jia-Yin Hou

  • Hung-I Yeh

  • Nguyen Ngoc Khoi Truong

  • Chung-Lieh Hung

  • July 13, 2026

Share

Correction: The Relationship Between Triglyceride-Glucose Index and Subclinical Left Ventricular Dysfunction

Background

The triglyceride-glucose (TyG) index is a potential biomarker for cardiovascular disease risk, particularly in the context of cardiovascular-kidney-metabolic (CKM) syndrome. Understanding its role in detecting subclinical myocardial impairment is crucial.

Data Highlights

No numerical data is presented in the correction article.

Key Findings

  • The ethics approval number was corrected from “No. 17MMHIS082e” to “Nos. 14MMHIS172, and 18MMHIS180e”.
  • The original study evaluated the relationship between the TyG index and left ventricular global longitudinal strain (GLS).
  • Subclinical left ventricular dysfunction (SLVD) was assessed in various stages of cardiovascular-kidney-metabolic syndrome.
  • The study highlights the need for accurate ethical reporting in clinical research.

Clinical Implications

Accurate reporting of ethical approvals is essential in research publications.

Conclusion

The correction of the ethics approval number highlights the importance of accurate documentation in clinical research.

Related Resources & Content

  1. Tsai K-Z et al., Frontiers in Endocrinology, 2026 -- Correction: The Relationship Between Triglyceride-Glucose Index and Subclinical Left Ventricular Dysfunction
  2. Frontiers in Endocrinology — Association of triglyceride–glucose and obesity-derived indices with the risk of aortic stenosis among individuals in cardiovascular–kidney–metabolic syndrome stages 0–3: a prospective cohort study from the UK Biobank
  3. Frontiers in Cardiovascular Medicine — The association between C-reactive protein-triglyceride glucose index and all-cause mortality in patients with cardiovascular-kidney-metabolic syndrome: a single-center retrospective cohort study
  4. Frontiers in Endocrinology — Impact of the longitudinal evolution of impaired fasting glucose on cardio-kidney-metabolic multimorbidity
  5. First-ever clinical guideline issued for cardiovascular-kidney-metabolic (CKM) syndrome | American Heart Association
  6. Clinical Applications of Strain Echocardiography – ASE
  7. Triglyceride-Glucose Index and Mortality Risk in the General Population: A Systematic Review and Meta-analysis of Prospective Studies | High Blood Pressure & Cardiovascular Prevention | Springer Nature Link

Original Source(s)

Related Content